LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Recruiting now · Not applicable
Conditions studied: Relapsed/Refractory Multiple Myeloma(MM)
In brief
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
Key facts
- Study ID
- NCT07100067
- Run by
- Nanjing Legend Biotech Co.
- People needed
- 35
- Starts
- 2025-09-16
- Expected to finish
- 2029-11-20
- Last updated by the study team
- 2025-12-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects voluntarily participate in clinical research.
- Age ≥18 years old.
- Eastern Cooperative Oncology Group (ECOG) score 0-2.
- Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria.
- Measurable lesions were present.
- Subjects have received treatment with one PI, one IMiD and a CD38 monoclonal antibody.
- Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria).
- Expected survival ≥3 months.
- Clinical laboratory values in the screening period meet criteria.
You may not qualify if…
- Received previous therapy targeting FcRH5 targets.
- Prior antineoplastic therapy and meet exclusion criteria (before apheresis);
- Subjects had Plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.
- Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;
- Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.
- Serious underlying diseases were present.
- Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.
- Also enrolled in other clinical studies.
Where it is running
- Institute of Hematology & Blood Diseases Hospital — Tianjin, China (enrolling)
- Institute of Hematology & Blood Diseases Hospital — Tianjin, China (enrolling)
- Wuhan Union Hospital — Wuhan, China (enrolling)
- Beijing Boren Hospital — Beijing, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.